Gut Hastalığı Tedavisi
Özet
Gut, monosodyum ürat kristallerinin birikmesiyle oluşan, prevalansı ve mortalitesi artan yaygın bir inflamatuvar artrittir. Tedavinin temel amaçları; akut atakları yönetmek, hiperürisemi ile komplikasyonları önlemek ve komorbiditeleri düzeltmektir. Asemptomatik hiperürisemide böbrek fonksiyonu normalse ilaç dışı yaşam tarzı değişiklikleri önerilirken, serum ürat seviyeleri çok yükseldiğinde tedavi düşünülür. Akut atakların ilk 24 saatinde kolşisin, NSAİİ'ler veya glukokortikoidler tercih edilir; kronik yönetimde ise allopürinol ve febuksostat gibi ürat düşürücü tedaviler (ULT) ile hedef serum ürat seviyesinin 6 mg/dL'nin altında tutulması hedeflenir. Kılavuzlar, ULT başlanırken mobilizasyon ataklarını önlemek adına 3-6 ay süreyle düşük doz profilaktik tedavi uygulanmasını ve hastaların diyet, hidrasyon ile komorbid durumlar açısından eğitilmesini güçlü şekilde önermektedir.
Gout is a common inflammatory arthritis characterized by the accumulation of monosodium urate crystals, with increasing prevalence and mortality rates. The primary goals of treatment are managing acute flares, preventing hyperuricemia and complications, and correcting comorbid conditions. In asymptomatic hyperuricemia, non-pharmacological lifestyle modifications are recommended if renal function is normal, whereas treatment is considered when serum urate levels are significantly elevated. Colchicine, NSAIDs, or glucocorticoids are preferred within the first 24 hours of acute flares; for chronic management, urate-lowering therapies (ULT) like allopurinol and febuxostat are used to maintain target serum urate levels below 6 mg/dL. Guidelines strongly recommend administering low-dose prophylactic treatment for 3 to 6 months during the initiation of ULT to prevent mobilization flares, alongside educating patients on diet, hydration, and the management of comorbid conditions.
Referanslar
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current opinion in rheumatology. 2011;34(2), 118–124.https://doi.org/10.1097/BOR.0000000000000861
Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis care & research. 2019;71(3), 427–434. https://doi.org/10.1002/acr.23607
Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment Options for Gout. Deutsches Arzteblatt international. 2017;114(13), 215–222. https://doi.org/10.3238/arztebl.2017.0215
Fessel WJ. Renal outcomes of gout and hyperuricemia. The American journal of medicine. 1979;67(1), 74–82. https://doi.org/10.1016/0002-9343(79)90076-7
Kumar M, Manley N, Mikuls TR. Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. Drugs & aging. 2021;38(7), 545–557. https://doi.org/10.1007/s40266-021-00866-2
Neogi T. Clinical practice. Gout. The New England journal of medicine. 2011;364(5), 443–452. https://doi.org/10.1056/NEJMcp1001124
Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and rheumatism. 2010;62(4), 1060–1068. https://doi.org/10.1002/art.27327
Aslam F, Michet C, Jr. My Treatment Approach to Gout. Mayo Clinic proceedings. 2017;92(8), 1234–1247. https://doi.org/10.1016/j.mayocp.2017.05.026
Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016;134(21), e468–e495. https://doi.org/10.1161/CIR.0000000000000456
Vargas-Santos AB, Neogi T. Management of Gout and Hyperuricemia in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017;70(3), 422–439. https://doi.org/10.1053/j.ajkd.2017.01.055
Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics. 2008;63(7), 13–20.
Schlesinger N. Treatment of acute gout. Rheumatic diseases clinics of North America. 2014;40(2), 329–341. https://doi.org/10.1016/j.rdc.2014.01.008
De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Annals of the rheumatic diseases. 2010;69(6), 1162–1164. https://doi.org/10.1136/ard.2009.122770
Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. The Journal of rheumatology. 1989;16(9), 1246–1248.
van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. The Journal of rheumatology. 1993;20(8), 1383–1385.
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & rheumatology (Hoboken, N.J.). 2020;72(6), 879–895. https://doi.org/10.1002/art.41247
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases. 2016;76(1), 29–42. https://doi.org/10.1136/annrheumdis-2016-209707
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research. 2012; 64(10), 1431–1446. https://doi.org/10.1002/acr.21772
Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis and rheumatism. 2002;47(4), 356–360. https://doi.org/10.1002/art.10511
Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Movement disorders : official journal of the Movement Disorder Society. 2010;25(2), 224–228. https://doi.org/10.1002/mds.22907
Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2008;22(2), 181–185. https://doi.org/10.1155/2008/870981
Becker MA, Schumacher HR, Jr., Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis and rheumatism. 2005;52(3), 916–923. https://doi.org/10.1002/art.20935
Becker MA, Schumacher HR, Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England journal of medicine. 2005;353(23), 2450–2461.
Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American journal of therapeutics. 2005;12(1), 22–34. https://doi.org/10.1097/00045391-200501000-00005
White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England journal of medicine. 2018;378(13), 1200–1210. https://doi.org/10.1056/NEJMoa1710895
Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet (London, England). 2020;396(10264), 1745–1757. https://doi.org/10.1016/S0140-
Zhang S, Xu T, Shi Q, et al. Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis. Frontiers in medicine. 2021;8, 698437. https://doi.org/10.3389/fmed.2021.698437
Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.The Journal of rheumatology. 2011; 38(9), 1957–1959. https://doi.org/10.3899/jrheum.110092
Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective - A review. Journal of advanced research. 2017;8(5), 495–511.https://doi.org/10.1016/j.jare.2017.04.008
Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford, England). 2010;49(1), 5–14. https://doi.org/10.1093/rheumatology/kep306
Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 1999;5(2), 49–55. https://doi.org/10.1097/00124743-199904000-00003
Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Drug safety. 2008;31(8), 643–665. https://doi.org/10.2165/00002018-200831080-00002
Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. Blood. 2001;97(10), 2998–3003. https://doi.org/10.1182/blood.v97.10.2998
Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2005;20(2), 431–433. https://doi.org/10.1093/ndt/gfh629
Botson JK, Tesser JRP, Bennett R, et al. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). The Journal of rheumatology. 2021;48(5), 767–774. https://doi.org/10.3899/jrheum.200460
Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet (London, England).2018;392(10156), 1403–1412. https://doi.org/10.1016/S0140-6736(18)32158-5
Yü T. The efficacy of colchicine prophylaxis in articular gout--a reappraisal after 20 years. Seminars in arthritis and rheumatism. 1982; 12(2), 256–264. https://doi.org/10.1016/0049-0172(82)90065-
Roddy E, Doherty M. Epidemiology of gout. Arthritis research & therapy. 2010;12(6), 223. https://doi.org/10.1186/ar3199
Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford, England). 2017;56(7), 1056–1059. https://doi.org/10.1093/rheumatology/kex150
Ben Salem C, Slim R, Fathallah N, et al. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford, England). 2017;56(5), 679–688. https://doi.org/10.1093/rheumatology/kew293
Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. P & T : a peer-reviewed journal for formulary management. 2014;39(10), 695–715.
Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi H. Low-dose aspirin use and recurrent gout attacks. Annals of the rheumatic diseases. 2014;73(2), 385–390. https://doi.org/10.1136/annrheumdis-2012-202589
